David W. J. Mcgirr Sells 3,250 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) Director David W. J. Mcgirr sold 3,250 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $71.30, for a total transaction of $231,725.00. Following the completion of the sale, the director now directly owns 100,723 shares in the company, valued at approximately $7,181,549.90. The trade was a 3.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Insmed Price Performance

Shares of Insmed stock opened at $73.69 on Thursday. Insmed Incorporated has a 52-week low of $55.74 and a 52-week high of $84.91. The stock has a market capitalization of $13.42 billion, a price-to-earnings ratio of -13.18 and a beta of 0.84. The company has a fifty day moving average of $69.32 and a 200-day moving average of $72.99. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $92.82 million during the quarter, compared to analysts’ expectations of $91.63 million. During the same period last year, the company posted ($1.06) EPS. Insmed’s revenue for the quarter was up 22.9% on a year-over-year basis. Equities research analysts expect that Insmed Incorporated will post -4.56 EPS for the current year.

Analyst Ratings Changes

INSM has been the topic of a number of recent analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. Morgan Stanley upped their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Wells Fargo & Company upped their price objective on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, Stifel Nicolaus decreased their price objective on shares of Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.73.

Institutional Investors Weigh In On Insmed

A number of institutional investors have recently made changes to their positions in the business. Strs Ohio purchased a new stake in shares of Insmed in the 1st quarter valued at $1,961,000. Intech Investment Management LLC boosted its stake in shares of Insmed by 43.2% in the 1st quarter. Intech Investment Management LLC now owns 101,979 shares of the biopharmaceutical company’s stock valued at $7,780,000 after purchasing an additional 30,752 shares in the last quarter. Bayforest Capital Ltd boosted its position in Insmed by 255.0% during the 1st quarter. Bayforest Capital Ltd now owns 7,054 shares of the biopharmaceutical company’s stock valued at $538,000 after buying an additional 5,067 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Insmed by 10.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 539,484 shares of the biopharmaceutical company’s stock valued at $41,157,000 after buying an additional 52,637 shares during the period. Finally, Woodline Partners LP boosted its position in Insmed by 53.3% during the 1st quarter. Woodline Partners LP now owns 248,770 shares of the biopharmaceutical company’s stock valued at $18,979,000 after buying an additional 86,540 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.